United States Patent 12,257,348: What the Claims Actually Cover and How the Landscape Closes In
US Drug Patent 12,257,348 (as characterized by the claim set provided) is directed to microcapsules that encapsulate solid benzoyl peroxide (BPO) in a silica-based shell built by layerwise precipitation onto oppositely charged surfaces, with release/dissolution-rate targets in defined test media, and with explicit process parameter windows (additives, acidification, temperature, and 3 to 50 shell-building cycles). Dependent claim coverage then expands to formulations and topical treatment methods, including fixed combinations with microencapsulated tretinoin and defined stability/out-of-spec degradation for the tretinoin component under accelerated storage.
1) What is claimed: the core microcapsule architecture
Claim 1 defines the invention in four layers
Claim 1 has four coupled limitations that matter for scope: (i) materials, (ii) dissolution release performance, (iii) the specific shell-building process, and (iv) the shell outcome (water-insoluble, silica-based multilayer).
A. Materials and structure
- Core: “solid benzoyl peroxide (BPO)”
- Shell: “silica based shell”
- Particle form: “microcapsule” with a “solid, water-insoluble particulate matter” formed by acidifying silicate solutions so silica coats precipitate onto the particle surface (steps b and d).
B. Release / dissolution performance
Claim 1 requires BPO to release at a target dissolution rate:
- 12% to 60% weight/h
- Measured in 55%:45% water:acetonitrile at ambient temperature.
This dissolution-rate clause becomes a hard gating limitation. Any competitor material that produces a silica shell but does not hit that dissolution window in the specified test medium is outside Claim 1.
C. Process architecture: charged surfaces + alternating precipitation
Claim 1 requires a multi-step deposition process:
-
Step (a): surface charging of BPO particulates
- Contact solid BPO particulate matter with:
- first cationic additive = cationic surfactant
- Condition: BPO particulates have positive surface charges (as stated).
- Output: dispersion in aqueous medium.
-
Step (b): first silica precipitation onto the cationically treated BPO
- Add aqueous silicate salt solution
- Under conditions where silicate salts precipitate onto the surface of the particulate matter
- Acidify to form solid, water-insoluble particulate matter
- The product “has a metal oxide layer coated thereon,” where Claim 4 makes the “metal oxide salt” explicitly silicate salt and the acid is one or more weak acids (citric/lactic).
-
Step (c): adhesion layer conditioning
- Contact the silica-coated particles with a “surface adhering additive” in aqueous medium:
- second cationic additive = cationic polymer and/or a non-ionic additive
- Output: dispersion with an adhering additive on the surface.
-
Step (d): further silica precipitation using sodium silicate
- Bring dispersion into contact with aqueous sodium silicate
- Precipitate onto the surface
- Acidify again to form a new solid, water-insoluble particulate matter with a further silica based layer.
-
Step (e): repeat c and d
- Repeat steps (c) and (d) between 3 and 50 times
- Temperature between 28°C and 40°C.
-
Step (f): optional aging
- Optional aging after repeating to obtain encapsulated BPO.
Business meaning: the patent is not only claiming “BPO@silica,” it is claiming a specific build-up method that uses cationic surfactant + alternating silica precipitation steps and cycle count + temperature.
2) How dependent claims narrow the shell-building chemistry and performance
Who are the add-on chemicals? (CTAC and PDAC)
- Claim 2: cationic surfactant is CTAC (cetyltrimethyl ammonium chloride) and/or cationic polymer is PDAC (poly(dimethyldiallylammonium chloride)), or a combination.
This is a meaningful narrowing: formulations using a different cationic surfactant/polymer may avoid Claim 2 but could still fall under Claim 1 if the “first cationic additive being a cationic surfactant” and “second cationic additive being a cationic polymer and/or non-ionic additive” are satisfied.
How many cycles?
- Claim 3: step (e) is between 5 and 7 times (i.e., 5 to 7 c/d repetitions).
Claim 1 allows 3 to 50. Claim 3 locks a narrower window that a competitor might use if they are trying to escape literal coverage for the exact repetition count.
Which acidification chemistry?
- Claim 4: acidifying step in (b) comprises addition of an acidic solution with at least one weak acid, and the metal oxide salt is a silicate salt.
- Claim 5: weak acid is citric acid, lactic acid, or mixture.
This is a second gating axis beyond dissolution rate: even if a competitor uses silica precipitation, using a non-weak-acid system (or a different acid set) can create a literal design-around.
What are the physical shell specs?
- Claim 6: average microcapsule diameter < 50 µm
- Claim 7: silica shell thickness 25 nm to 3000 nm
- Claim 8: stability ~2 weeks to 3 years at room temperature
These are not just properties. They can become claim-limiting if asserted under infringement theories tied to a specific product spec.
3) Formulation scope: suspensions, compositions, and vehicle types
Microcapsule delivery
- Claim 9: a suspension comprising the Claim 1 microcapsule.
- Claim 10: a pharmaceutical composition including the microcapsules and a pharmaceutically acceptable carrier/excipient.
Vehicle breadth
- Claim 12 and 13: carriers include:
- ointment, cream, lotion, oil, solution, emulsion, gel, paste, milk, aerosol, powder, foam
This is broad topical formulation coverage and supports product format flexibility for a skincare/derm segment.
Microencapsulation efficiency
- Claim 14 and 15: microencapsulation efficiency at least 75%.
Again, literal scope can turn on how “microencapsulation efficiency” is measured and whether competitor data meets that threshold. The claim itself sets the number.
4) Combo therapy claims: BPO + tretinoin in matched microcapsule formats
BPO fixed loading + tretinoin fixed loading
- Claim 16: composition where:
- BPO microcapsules are ~3% by weight
- and tretinoin microcapsules are ~0.1% by weight
- plus pharmaceutically acceptable carrier/excipient.
Tretinoin microcapsules are also claimed, with their own performance metrics
- Claim 17: includes tretinoin microcapsules:
- core: tretinoin in solid form
- shell: shell microencapsulation
- tretinoin microencapsulation efficiency at least 90%
This claim turns the patent into a dual-microencapsulation architecture, not merely a BPO microcapsule with optional tretinoin.
Tretinoin concentration in the core
- Claim 18: tretinoin concentration above 14% w/w within the core.
Matched dissolution-rate windows in different media
Tretinoin stability under accelerated conditions
- Claim 22 and 24: after:
- two weeks at 40°C and 75% relative humidity
- concentration of all-trans 5,6-epoxy retinoic acid < 1% by weight of initial tretinoin amount
- Claims 22 and 24 apply in different dependent contexts (claim 17 and claim 16 respectively).
This clause is a concrete stability KPI. It narrows the claimed commercial-quality phenotype of the formulation.
5) Methods of use: topical treatment and indication breadth
Generic dermatology label
- Claim 25 and 26: method for treating skin disease selected from:
- acne, psoriasis, seborrhea, contact dermatitis, rosacea
- Topically administer pharmaceutical composition corresponding to Claims 10 and 11 respectively.
Combo treatment uses
- Claim 27 and 29: method using compositions under Claims 16 and 17 respectively, same indication set.
- Claim 28 and 30: add microencapsulation efficiency thresholds into the treatment method claims:
- BPO efficiency ≥75%
- tretinoin efficiency ≥90%
Rosacea-specific method claims
- Claim 31: rosacea method using composition of Claim 10 with BPO microcapsule efficiency ≥75%
- Claim 32: same but for Claim 11
The method claims are broad for indication. If the product contains the microcapsule system, the labeling set is already covered at claim level.
6) Patent landscape implications: where competitors can and cannot land
Because the claim set is heavily parameterized, the competitive “design-around map” has predictable pressure points:
A. Literal infringement hinges on the dissolution targets
- BPO: 12% to 60% weight/h in 55:45 water:acetonitrile at ambient
- Tretinoin: 5% to 35% weight/h in 30:70 water:isopropyl alcohol at 32°C
A silica shell that changes porosity or hydration dynamics will shift dissolution. Competitors need product testing to avoid falling into these windows.
B. Literal infringement hinges on the deposition process steps
Claim 1’s sequence is specific:
- BPO + cationic surfactant to obtain a positive-charge particulate dispersion
- silica precipitation using silicate salt and acidification
- surface adhesion step using cationic polymer and/or non-ionic additive
- further silica precipitation using sodium silicate and acidification
- 3-50 cycles of c/d at 28°C-40°C
- optional aging
Design-around tends to come from changing either:
- the charged build-up logic (using different polymers/surfactants),
- the acid system,
- replacing precipitation with sol-gel crosslinking,
- operating outside the temperature range,
- or changing cycle count (to avoid Claim 3’s 5-7 subset and, ideally, avoiding Claim 1’s 3-50 window).
C. Product-level KPIs are also claim-limiting
- Particle size: < 50 µm
- Shell thickness: 25 nm to 3000 nm
- Encapsulation efficiency:
- Tretinoin impurity formation: all-trans 5,6-epoxy retinoic acid <1% after 2 weeks at 40°C/75% RH
Competitors can attempt to match microcapsule release behavior while changing efficiencies or stability outcomes, but those are explicitly claimed.
D. Formulation-level breadth increases enforcement surface
The vehicle list is broad. That means enforcement can reach:
- creams, gels, aerosols, foams, powders, etc.,
so long as the composition includes the claimed microcapsule system and meets KPIs.
7) Scope summary: claim coverage perimeter
Claim 1: “BPO@silica” plus a defined shell build method and dissolution gate
Covers:
- solid BPO core
- silica-based shell made by silica precipitation with acidification and adhesion layer conditioning
- BPO dissolution 12%-60% w/h in 55:45 water:acetonitrile at ambient
- repeated c/d cycling 3-50 times at 28-40°C
- optional aging
Claims 2-8: chemistry and physical product specs
- CTAC and PDAC variants
- 5-7 cycles subset
- weak acid (citric/lactic) acidification subset
- size <50 µm
- shell thickness 25-3000 nm
- storage stability window 2 weeks to 3 years
Claims 9-15: formulation delivery and efficiency
- suspensions and topical compositions
- microencapsulation efficiency thresholds
Claims 16-24: fixed combination and stability of tretinoin
- BPO ~3% w/w and tretinoin ~0.1% w/w
- tretinoin microcapsules efficiency ≥90%
- dissolution windows for both actives
- accelerated stability impurity criterion
Claims 25-32: methods for acne/psoriasis/etc. and rosacea
- topical administration, indication set, and inclusion of KPIs in combo method claims
Key Takeaways
- US 12,257,348 is process-and-performance coupled. It claims not only a silica-encapsulated BPO product, but a layer-build procedure (cationic surfactant and adhesion additive, silica precipitation with acidification, 3-50 c/d cycles at 28-40°C) plus a BPO dissolution-rate window in a specific solvent mixture.
- The family is enforceable across formulation types. Vehicle language is broad, so the claim set targets the microcapsule system rather than restricting product form factors.
- Combo coverage is tight. BPO plus tretinoin is claimed with fixed weight percentages, separate efficiency thresholds, separate dissolution test media/windows, and an accelerated stability impurity limit for tretinoin.
- Competitors’ main design-around levers are measurable. Dissolution rate, cycle count, acid type, adhesion layer chemistry, shell thickness/size, and encapsulation efficiency are all explicit claim gates.
FAQs
-
Does the patent cover any silica shell over BPO, or only those made by the stated precipitation/cycle process?
It covers microcapsules meeting Claim 1’s process limitations and BPO dissolution window. A silica shell made outside those steps is unlikely to meet Claim 1.
-
Can a competitor use a different cationic surfactant/polymer and still fall under the broadest claim?
Yes for Claim 1 in principle, because it requires “a cationic surfactant” and “a cationic polymer and/or non-ionic additive,” but the product must still meet dissolution and process constraints; CTAC/PDAC are only explicitly set in Claim 2.
-
Is the dissolution test media part of the claim scope?
Yes. Both BPO and tretinoin dissolution rates are tied to specific water:organic mixtures and temperatures in the dependent claims.
-
Is the tretinoin stability/impurity limit required only for the combo product, or also for BPO-alone?
It appears in the tretinoin combination dependency (Claims 17-related), tying a specific impurity threshold to accelerated storage conditions.
-
What topical diseases are covered by the method claims?
Acne, psoriasis, seborrhea, contact dermatitis, and rosacea, plus rosacea-specific method claims.
References
[1] United States Patent No. 12,257,348 (claim set provided by user).
